v3.25.2
Fair Value Measurements - Narrative (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 21, 2025
USD ($)
Jan. 31, 2023
USD ($)
payment
performance_period
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Contingent consideration     $ 4,940,000   $ 4,940,000   $ 0  
Change in estimated fair value of contingent consideration     140,000 $ (1,195,000) 140,000 $ (1,195,000)    
Alphazyme                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Contingent consideration     0   0      
Fair value of contingent consideration   $ 5,300,000            
Number of payments | payment   3            
Number of performance periods | performance_period   3            
Payment for contingent consideration             $ 0 $ 0
Change in estimated fair value of contingent consideration       $ (1,200,000)   $ (1,200,000)    
Alphazyme | Measurement Input, Discount Rate                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Contingent consideration liability, measurement input   0.178            
Alphazyme | SPA, Maximum Performance Payment                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Contingent consideration   $ 75,000,000.0 25,000,000.0   25,000,000.0      
Officinae Bio                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Contingent consideration $ 35,000,000.0              
Fair value of contingent consideration $ 4,800,000              
Change in estimated fair value of contingent consideration     $ 100,000   $ 100,000      
Officinae Bio | Measurement Input, Probability of Achievement                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Contingent consideration liability, measurement input 1.000              
Officinae Bio | Measurement Input, Discount Rate                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Contingent consideration liability, measurement input 0.073              
Officinae Bio | Milestone Consideration                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Contingent consideration $ 5,000,000.0